ClinicalTrials.gg
RecruitingNCT07554898Updated May 11, 2026

Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma

A Phase 2 interventional study of Orelabrutinib and Ultra-low-dose Radiation Therapy in MALT Lymphoma, sponsored by Zhejiang Cancer Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Zhejiang Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone — 17 open to participants now, 21 under way, 1 of them phase 3. orelabrutinib · Lymphoma, B-Cell, Marginal Zone.

Planned enrollment
10th of 21
60 · median 51
Started
2026
with 3 others
Phase 2
17 of 21
13 open now
Primary completion
2028-02
later than 13 of 20 live
Registered
19th of 21
by date

Among the 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone, this one is the 10th largest by planned enrollment, is one of 4 that started in 2026, is one of 17 in phase 2, reaches primary completion later than 13 of the 20 other live ones, and was the 19th registered.

Lymphoma, B-Cell, Marginal Zone

877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

17 of the 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone, or all of them as a file.
02

Study summary

This is a prospective, multicenter Phase 2 clinical trial named the MALT-RO study, evaluating ultra-low-dose radiation therapy followed by orelabrutinib as first-line treatment for adults with Stage I-II MALT lymphoma. The study aims to determine the efficacy and safety profile of this sequential regimen. Eligible participants aged 18 years or older with histologically confirmed MALT lymphoma, measurable lesions, no prior systemic anti-lymphoma therapy, adequate organ function, and an ECOG performance status of 0-1 will receive 4Gy ultra-low-dose radiation (2Gy daily for 2 consecutive days) followed by oral orelabrutinib 150mg once daily for up to 6 cycles (28 days per cycle). Patients with partial response or stable disease after 6 cycles may continue orelabrutinib monotherapy for up to 12 cycles or until disease progression. All participants will undergo regular safety monitoring, tumor assessments, and long-term follow-up every 3 months to evaluate treatment durability. This treatment strategy is designed to improve efficacy and achieve more favorable outcomes compared with standard approaches for MALT lymphoma, while minimizing treatment-related toxicities such as long-term organ damage, xerostomia, cataracts, and other complications related to conventional standard-dose radiation, thereby offering a well-tolerated, convenient, targeted therapeutic option for patients with MALT lymphoma under strict ethical oversight in accordance with the Declaration of Helsinki and Chinese Good Clinical Practice guidelines.

03

Conditions studied

  • MALT Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years, all genders eligible;
  2. Histopathologically confirmed MALT lymphoma (extranodal marginal zone lymphoma) with at least one outside the spleen, with any diameter > 1.0 cm;
  3. No prior systemic anti-tumor therapy after diagnosis (including chemotherapy, targeted therapy, rituximab, etc.).

    Note: For patients with primary gastric MALT lymphoma, Helicobacter pylori (HP) must be negative or the patient must have failed standard HP eradication therapy. Patients with MZL who progressed or after local treatment (including surgery, Helicobacter pylori eradication, and treatment) are eligible for enrollment.

  4. performance status score of 0-1;
  5. Presence of treatment indications as judged by the investigator (including symptoms, cytopenias, risk of end-organ damage, bulky disease, or persistent progression);
  6. Adequate major organ function, meeting the following criteria:

    1. (ANC) ≥ 1.5 × 10⁹/L, ≥ 75 × 10⁹/L, ≥ 75 g/L; If bone marrow involvement is present: ANC ≥ 1.0 × 10⁹/L, platelets ≥ 50 × 10⁹/L, hemoglobin ≥ 50 g/L;
    2. Total ≤ 1.5 × , or ALT ≤ 2 × ULN, serum creatinine ≤ 1.5 × ULN, serum amylase ≤ ULN;
    3. (INR) ≤ 1.5 × ULN.
  7. Expected survival ≥ 3 months;
  8. Voluntarily provide written before screening.

Exclusion criteria

Exclusion Criteria:

  1. Current or history of other malignant tumors, except for those who have achieved complete remission after radical treatment;
  2. Lymphoma involvement of the central nervous system or transformation to high-grade lymphoma;
  3. Patients with other tumors who have not recovered from non-hematologic toxicities of prior anti-tumor therapy to ≤ Grade 1 (except for alopecia);
  4. Uncontrolled or significant cardiovascular diseases, including:

    1. Congestive heart failure of (NYHA) Class II or above, unstable angina, myocardial infarction within 6 months before the first dose of the study drug, or arrhythmias requiring treatment at screening, or (LVEF) \< 50%;
    2. Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, or unclassified cardiomyopathy);
    3. History of prolongation, or QTc interval at screening > 470 ms for females or > 450 ms for males;
    4. Subjects with symptomatic coronary artery disease requiring medication;
    5. Uncontrolled hypertension (despite lifestyle modification and use of a reasonable and tolerable maximum dose of 3 or more antihypertensive drugs [including diuretics] for more than 1 month, blood pressure still not reaching target, or blood pressure can only be effectively controlled with 4 or more antihypertensive drugs);
  5. Active bleeding within 2 months before screening, or currently receiving anticoagulant drugs, or considered by the investigator to have a clear bleeding tendency;
  6. Urine protein ≥ 2+ and 24-hour urine protein quantification ≥ 2 g/24 hours;
  7. History of deep vein thrombosis or pulmonary embolism within the past 6 months;
  8. History of organ transplantation or hematopoietic stem cell transplantation;
  9. Major surgery within 6 weeks before screening or minor surgery within 2 weeks before screening. Major surgery is defined as surgery performed under general anesthesia; however, diagnostic endoscopic procedures are not considered major surgery. Insertion of vascular access devices is exempt from this exclusion criterion;
  10. /AIDS or other serious infectious diseases;
  11. Patients with severe pulmonary function impairment due to pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, or other conditions;
  12. Previous treatment with BTK inhibitors, BCR pathway inhibitors (e.g., PI3K, Syk), or BCL-2 inhibitors;
  13. Subjects with drug abuse or alcohol abuse;
  14. Pregnant or lactating women, or subjects of who are unwilling to use measures;
  15. Other conditions that, in the opinion of the investigator, make the subject unsuitable for participation in this trial.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Ultra-low-dose Radiation Followed by Orelabrutinib

    All participants will receive a sequential treatment regimen: ultra-low-dose radiation therapy (total 4Gy, administered as 2Gy daily for 2 consecutive days), followed by oral orelabrutinib 150mg once daily for up to 6 cycles (28 days per cycle). Patients who achieve partial response or stable disease without disease progression after 6 cycles may continue orelabrutinib monotherapy for up to 12 cycles or until progression.

    Drug: Orelabrutinib · Radiation: Ultra-low-dose Radiation Therapy

Interventions

  • Orelabrutinib 150 mg tablets, administered orally once daily. Treatment consists of up to 6 consecutive 28-day cycles. Patients with partial response or stable disease without disease progression after 6 cycles may continue orelabrutinib monotherapy for up to 12 cycles.

  • RadiationUltra-low-dose Radiation Therapy

    The total radiation dose is 4 Gy, administered as 2 Gy per day for 2 consecutive days.

06

What researchers measure

Primary outcomes

  1. Complete Remission Rate (CRR)

    Complete remission is defined as the disappearance of all target lesions and no new lesions appearing, assessed per the Lugano Response Criteria for Lymphoma.

    Time frame: Assessed at the end of the treatment (approximately 6 cycles, up to 6 months from study start) .

  2. Incidence of Adverse Events

    Safety outcomes include the incidence, severity, and relationship to treatment of all adverse events (AEs) and serious adverse events (SAEs) monitored throughout the treatment and follow-up period.

    Time frame: Throughout the treatment period and during the follow-up period (up to 12 months or until disease progression).

Secondary outcomes

  1. Objective Response Rate (ORR)

    To evaluate the objective response rate (defined as the proportion of participants achieving complete remission \[CR\] or partial remission \[PR\]) in participants with Stage I-II MALT lymphoma treated with the sequential regimen, assessed per the Lugano Response Criteria.

    Time frame: 3-month, 6-month, and 12-month follow-up visits.

  2. Duration of Response (DOR)

    To assess duration of response, defined as the time from the first documentation of objective response (CR or PR) to disease progression, recurrence, or death from any cause, per Lugano Response Criteria.

    Time frame: Assessed every 3 months up to 24 months after study initiation.

  3. Time to Response (TTR)

    To evaluate time to response, defined as the time from study enrollment to the first documentation of objective response (CR or PR), assessed per the Lugano Response Criteria.

    Time frame: Assessed at each on-treatment visit (every 4 weeks during 6 cycles of orelabrutinib) and follow-up visits.

  4. Progression-Free Survival (PFS)

    To assess progression-free survival, defined as the time from study enrollment to disease progression, recurrence, or death from any cause, per Lugano Response Criteria.

    Time frame: Assessed every 3 months up to 24 months after study initiation.

  5. Overall Survival (OS)

    To evaluate time from study enrollment to death from any cause.

    Time frame: 24 months

07

Study locations

2 of 2 sites recruiting
  • No. 1, East Banshan Road , Gongshu District
    Hangzhou, Zhejiang 310000, China
    Recruiting
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Feb 2028, 21 months later.

Of 97 non-industry phase 2 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 21 months is below that.

Counting every sponsor, half of 113 studies reached it within 69 months; a quarter within 38 and three quarters within 110.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Apr 28, 2026
StartEst.
Apr 16, 2026
Primary completionEst.
Feb 1, 2028
CompletionEst.
Jan 1, 2029
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07554898
Collaborators
Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital of Zhejiang University, Zhejiang Provincial People's Hospital, Zhejiang Provincial Tongde Hospital, Changxing County Traditional Chinese Medicine Hospital
Responsible party
TanYamin (Chief Physician, Zhejiang Cancer Hospital) — Principal investigator
First posted
Apr 28, 2026
Start date
Apr 16, 2026 (estimated)
Primary completion
Feb 1, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
May 11, 2026

Study contacts

Xiaolin Yuan, MD
Contact
yuanxiaolinhaha@163.com
8657188122153
Yamin Tan, phD
principal investigator · Zhejiang Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion